Heng‐Huan Lee

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

32h-index7.8kcitations124works3.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(17), CAR-T cell therapy research(17), PARP inhibition in cancer therapy(14), Cancer Immunotherapy and Biomarkers(12), Chronic Lymphocytic Leukemia Research(12)

Publications124 total

Correction: The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma
Experimental Hematology and Oncology·2026Open Access
The switch of TCA cycle mode determines the fate of pirtobrutinib-tolerant persister cells
Blood·2025Open Access
POSTER: MCL-088 Using Artificial Intelligence to Overcome Resistance to CAR-T Therapy in Mantle Cell Lymphoma
Clinical Lymphoma Myeloma & Leukemia·2025
MCL-088: Using Artificial Intelligence to Overcome Resistance to CAR-T Therapy in Mantle Cell Lymphoma
Clinical Lymphoma Myeloma & Leukemia·2025
SOX11 modulates BCR signaling through the PAX5/CD19 axis for therapeutic targeting in BTK-resistant mantle cell lymphoma
Blood Advances·2025· 2 citedOpen Access
BCL-2/BCL-XL dual inhibition triggers Gasdermin D-mediated pyroptosis in mantle cell lymphoma
Cancer Letters·2025· 2 citedOpen Access
TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma
Blood·2025· 4 citedOpen Access
RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer
Signal Transduction and Targeted Therapy·2025· 3 citedOpen Access
Novel Insights into SOX11 Modulation of BCR Signaling and Targeting of BTK Resistance
Blood·2024· 1 citedOpen Access
All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer
2024· 3 citedOpen Access
SOX11 Inhibits BCR Signaling Through the PAX5/CD19 Axis for Therapeutic Targeting in BTK and BCL2 Inhibitor Resistant Mantle Cell Lymphoma
Clinical Lymphoma Myeloma & Leukemia·2024
MCL-762 SOX11 Inhibits BCR Signaling Through the PAX5/CD19 Axis for Therapeutic Targeting in BTK and BCL2 Inhibitor Resistant Mantle Cell Lymphoma
Clinical Lymphoma Myeloma & Leukemia·2024
Abstract 649: SOX11 regulates BCR signaling via the PAX5/CD19 axis in MCL
Cancer Research·2024· 1 cited
Abstract 676: The integrated stress activator BTM-3566 overcomes therapeutic resistance in mantle cell lymphoma
Cancer Research·2024
Abstract 33: Revitalizing CAR-T cells for TNBC: Targeting phosphorylation of TCF7 to overcome T cell exhaustion
Cancer Research·2024· 1 cited
The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma
Experimental Hematology and Oncology·2024· 22 citedOpen Access
Targeting ALK averts ribonuclease 1-induced immunosuppression and enhances antitumor immunity in hepatocellular carcinoma
Nature Communications·2024· 17 citedOpen Access
Exploring BiTE-Integrated CAR T-Cell Therapy to Overcome Tumor Antigen Escape and Reinforce CAR-T Therapy in Mantle Cell Lymphoma
Blood·2023· 4 cited
The Reversible BTK Inhibitor Nemtabrutinib Demonstrates Favorable Antitumor Efficacy and Enhances the Function of CAR T Cells in Mantle Cell Lymphoma
Blood·2023· 3 cited
Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins
Cell Death and Disease·2023· 8 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Mien‐Chie Hung(38), Weiya Xia(22), Ying‐Nai Wang(21), Jennifer L. Hsu(17), Hirohito Yamaguchi(15), Li-Chuan Chan(14), Dihua Yu(12), Gabriel N. Hortobágyi(11), Yongkun Wei(10), Sam S. Chang(9), Jung-Mao Hsu(9), Chia‐Wei Li(8), Seung-Oe Lim(8), Jong‐Ho Cha(8), Chao‐Kai Chou(8), Jun Yao(7), Chun‐Te Chen(7), Shao‐Chun Wang(7), Wenhao Yang(6), Wen-Hsuan Yu(5)